<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Moxifloxacin (ophthalmic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Moxifloxacin (ophthalmic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Moxifloxacin (ophthalmic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9819" href="/d/html/9819.html" rel="external">see "Moxifloxacin (ophthalmic): Drug information"</a> and <a class="drug drug_patient" data-topicid="12262" href="/d/html/12262.html" rel="external">see "Moxifloxacin (ophthalmic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9347894"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Moxeza [DSC];</li>
<li>Vigamox</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869458"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Moxifloxacin [DSC];</li>
<li>AG-Moxifloxacin;</li>
<li>APO-Moxifloxacin;</li>
<li>JAMP-Moxifloxacin;</li>
<li>PMS-Moxifloxacin;</li>
<li>SANDOZ Moxifloxacin;</li>
<li>Vigamox</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F11164141"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Fluoroquinolone</span>;</li>
<li>
<span class="list-set-name">Antibiotic, Ophthalmic</span></li></ul></div>
<div class="block don drugH1Div" id="F53462666"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="66667e5a-50c3-4a01-9a02-3f19aeac051d">Bacterial conjunctivitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bacterial conjunctivitis:</b> Term neonate: Ophthalmic: Vigamox: Instill 1 drop into affected eye(s) 3 times daily for 7 days; has been used in neonates beginning at birth.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F9348047"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="66667e5a-50c3-4a01-9a02-3f19aeac051d">Bacterial conjunctivitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bacterial conjunctivitis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Moxeza: Infants â‰¥4 months, Children, and Adolescents: Ophthalmic: Instill 1 drop into affected eye(s) 2 times daily for 7 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Vigamox: Infants, Children, and Adolescents: Ophthalmic: Instill 1 drop into affected eye(s) 3 times daily for 7 days.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51130356"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, adjustment unlikely needed due to low systemic absorption.</p></div>
<div class="block dohp drugH1Div" id="F51130357"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, adjustment unlikely needed due to low systemic absorption.</p></div>
<div class="block doa drugH1Div" id="F9348048"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9819" href="/d/html/9819.html" rel="external">see "Moxifloxacin (ophthalmic): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="66667e5a-50c3-4a01-9a02-3f19aeac051d">Bacterial conjunctivitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bacterial conjunctivitis: Ophthalmic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Moxeza: Instill 1 drop into affected eye(s) 2 times daily for 7 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Vigamox: Instill 1 drop into affected eye(s) 3 times daily for 7 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis (off-label use):</b> Instill 1 drop into operative eye every 5 to 15 minutes for five doses within the hour prior to the start of the procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>). <b>Note:</b> Prophylactic administration has ranged from preoperatively (including day of surgery only to 1 to 3 days preoperatively), intraoperatively, at end of procedure, and postoperatively. However, no specific recommendations beyond immediate preoperative use, including duration of prophylaxis, can be made due to insufficient evidence. A total duration (pre- and postoperatively) of up to 15 days has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981','lexi-content-ref-17980093','lexi-content-ref-Speaker.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981','lexi-content-ref-17980093','lexi-content-ref-Speaker.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991669"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doha drugH1Div" id="F50988978"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption. </p></div>
<div class="block adr drugH1Div" id="F9347977"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (1% to 6%), decreased visual acuity (1% to 6%), dry eye syndrome (1% to 6%), eye discomfort (1% to 6%), eye irritation (1% to 2%), eye pain (1% to 6%), eye pruritus (1% to 6%), keratitis (1% to 6%), lacrimation (1% to 6%), ocular hyperemia (1% to 6%), subconjunctival hemorrhage (1% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otitis media (1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Increased cough (1% to 4%), pharyngitis (1% to 4%), rhinitis (1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (1% to 4%)</p></div>
<div class="block coi drugH1Div" id="F9347974"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Moxeza ophthalmic solution: There are no contraindications listed in manufacturer's labeling</p>
<p style="text-indent:-2em;margin-left:2em;">Vigamox: Hypersensitivity to moxifloxacin, other quinolone antibiotics, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F9347975"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">â€¢ Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis, angioedema, and dermatologic reactions, have been reported with systemic use of moxifloxacin. Discontinue use if an allergic reaction occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">â€¢ Superinfection: Prolonged use may lead to overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, discontinue use and institute appropriate alternative therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">â€¢ Toxic anterior segment syndrome: Toxic anterior segment syndrome, which may consist of corneal edema, fibrin, cell or flare, hypopyon, keratic precipitates, or vitreous opacities, has occurred with intraocular administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">â€¢ Ophthalmic solution: For topical ophthalmic use only. Not for subconjunctival injection or for direct introduction into the anterior chamber of the eye. Contact lenses should not be worn during therapy.</p></div>
<div class="block foc drugH1Div" id="F9348142"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Moxeza: 0.5% (3 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vigamox: 0.5% (3 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5% (3 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5% (3 mL)</p></div>
<div class="block geq drugH1Div" id="F9347897"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F9348144"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Moxifloxacin HCl (2X Day) Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $61.09</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Moxifloxacin HCl Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $4.64 - $58.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Vigamox Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $80.37</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869459"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vigamox: 0.5% (1 mL, 3 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5% (3 mL)</p></div>
<div class="block admp drugH1Div" id="F52614383"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">For topical ophthalmic use only; not for injection. Avoid touching tip of applicator to eye, finger, or other surfaces. Apply gentle pressure to lacrimal sac during and immediately following instillation (1 minute) or instruct patient to gently close eyelid after administration, to decrease systemic absorption of ophthalmic drops (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8100087','lexi-content-ref-6704011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8100087','lexi-content-ref-6704011'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F11457044"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">For topical ophthalmic use only; not for injection. Avoid touching tip of applicator to eye or other surfaces.</p></div>
<div class="block sts drugH1Div" id="F9348011"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 2Â°C to 25Â°C (36Â°F to 77Â°F).</p></div>
<div class="block usep drugH1Div" id="F53570672"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of bacterial conjunctivitis caused by susceptible organisms: <i>Acinetobacter lwoffii</i>, <i>Aerococcus viridans</i>, <i>Corynebacterium </i>spp, <i>Enterococcus faecalis</i>, <i>Micrococcus luteus</i>, <i>Staphylococcus arlettae</i>, <i>Staphylococcus</i>
<i> aureus</i>, <i>Staphylococcus</i>
<i> capitis</i>, <i>Staphylococcus</i>
<i> epidermidis</i>, <i>Staphylococcus</i>
<i> haemolyticus</i>, <i>Staphylococcus</i>
<i> hominis</i>, <i>Staphylococcus</i>
<i> saprophyticus</i>, <i>Staphylococcus</i>
<i> warneri</i>, <i>Streptococcus viridans </i>spp, <i>Streptococcus</i>
<i> pneumoniae</i>, <i>Escherichia coli</i>, <i>Haemophilus influenzae</i>, <i>Haemophilus</i>
<i> parainfluenzae</i>, <i>Klebsiella pneumoniae</i>, <i>Cutibacterium acnes</i>, <i>Chlamydia trachomatis</i> (Vigamox: FDA approved in all ages; Moxeza: FDA approved in ages â‰¥4 months and adults).</p></div>
<div class="block mst drugH1Div" id="F9347832"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Vigamox [U.S., Canada, and multiple international markets] may be confused with Fisamox brand name for amoxicillin [Australia]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299728"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F9347982"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F9775710"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">When administered orally or IV, moxifloxacin crosses the placenta (OzyÃ¼ncÃ¼ 2010a; OzyÃ¼ncÃ¼ 2010b). The amount of moxifloxacin available systemically following topical application of the ophthalmic drops is limited and significantly less in comparison to oral or IV doses.</p>
<p style="text-indent:0em;margin-top:2em;">If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctal occlusion for 3 to 5 minutes after application to decrease potential exposure to the fetus (Samples 1988).</p></div>
<div class="block mopp drugH1Div" id="F53570671"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs of infection.</p></div>
<div class="block pha drugH1Div" id="F9348014"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Moxifloxacin is a DNA gyrase inhibitor, and also inhibits topoisomerase IV. DNA gyrase (topoisomerase II) is an essential bacterial enzyme that maintains the superhelical structure of DNA. DNA gyrase is required for DNA replication and transcription, DNA repair, recombination, and transposition; inhibition is bactericidal.</p></div>
<div class="block phk drugH1Div" id="F46147221"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Absorption: Minimal systemic absorption; resulting serum concentration was 0.02% of that achieved with oral formulation</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961993"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Imox | Moxigram | Vigamox</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Flomox | Moflag | Moxidrop | Vigamox</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Cinagen xg | Flomox | Floromox | Floxalone | Floximox | Iventi | Mfc | Moxif | Moxigen | Moxigen xg | Moxigram | Moxikem | Moxivin | Moxquin | Odycin | Optimox | Optimox xg | Visomox</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Kanavig</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Apdrops | Mo floren</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Moxifloxan | Vigamox | Xiflodrop</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Vigamox</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Vigamox</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">CÃ´te d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Apdrops | Mo floren | Moxiflal</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Megrelan | Moxof | Quimox | Vigamox</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Floxma | Moxflodel | Moxifloxacino | Moxilab | Moxipharm | Oftalmotrimox | Oftamox | Quimox | Vigamox | Vitalmox | Willmox</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Moxifloxacin olikla | Vigamox</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Moxifloxacin Micro Labs | Vigamox</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Monafox</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Azon | Ixmu | Micoftal | Moxiquinol | Moxof | Siccina | Vigamox</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Lamoflox | Moflag | Moxof</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Lifodrox | Vigamox</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Depzabid | Eliocuban | Fluroquinomox | Fortymox | Mograflox | Moxiflox | Moxyseyaro | Vigamox</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Abimox | Moxifloxacino kern pharma | Vigamox</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Eyemox | Fortymox | Mosi | Moxifloxacin | Moxifloxan | Moxigram | Moxista</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Vigamox</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Moxivig</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Vigamox</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Vigamox</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Moksacin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Vigamox</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Molcin | Moxidrop | Moxifloxacin HCL | Vigamox</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Moxivig</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">4 Quin | Akuvitis | Apdrops | Apdrops xg | Aromoxi | Centaflox | Congimox | Emfozen | Eye Quin | Floxview | Gb Mox | K moxi | Lupin's mxg | Mahaflox | Maxim | Mfc | Mflotas | Milflox | Mlobe | Mo 4 | Mo floren | Mosi | Moxiblu | Moxicip | Moxieye | Moxifax | Moxigram | Moxilone | Moximac | Moximum | Moxiset | Moxisurge | Moxitak | Moxiview | Moxluv | Moxoft | Moxyma | Mxc | Mxy | Occumox | Qpflox | Raymoxi | Senzmox | Tagamox | Thomoxx | Vigamox | Vigoquin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Oxa | Vigamox</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Fortymox | Imox | Vigamox</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Moxifloxacin sandoz | Vegamox</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Apdrops | Mflox | Milflox | Mo floren | Moxoft | Oxin | Vigamox</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aucomox | Bimox | Eye moxi | Eyemox | Eymox | Flonacin | Huons moxyfloxacin | K moxi | Lightmoxi | Litemoxi | Moroxacin | Moxi i | Moxiain | Moxibella | Moxibit | Moxibru | Moxiflan | Moxifle | Moxiflem | Moxiflo | Moxiforce | Moxihue | Moxikacin | Moxista | Moxitacin | Moxitan | Moxitra | Moxitwo | Ophthalocin | Optimox | Unifle | Vigaflo | Vigamox</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Vigamox</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Fortymox | Vigamox</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ekara | Lifodrox | Vigamox</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Kanavig</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ekara | Lifodrox | Vigamox</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Vigamox</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Avelux | Mifloko | Vigamoxi</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Mosi | Moxifcin | Vigamox | Zanaflox</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Micromox | Moxifloxacin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Vigamox</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Vigamox</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Vigamox</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Akamoxx | Citol moxifloxacin | Cubris | Lamoflox | Moxof | Unimox | Vigamox</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Amoxiflox | Occumox | Vigamox | Vistamox</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cemox | Fotiflox | Inmox | Izilon | Maxcare | Medimox | Megamox | Mexoflox | Mionex | Moxear | Moxicin | Moxifloxacin | Moxilab | Moxiopt | Moxirains | Moxiral | Moxopt | Moxotic | Narmox | Ocumox | Opmox | Oxcin | Q mox | Raymox | Selmoxi | Valamox | Vigamox | X gen | Xemox | Xomelox</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Floxamic | Floxamic Neo | Monafox | Vigamox</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Moxeza | Moxifloxacin | Moxifloxacin ophthalmic | Vigamox</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Moflok | Vigamox</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Moflag | Moxi oftalmol | Moxipron | Moxof | Vigamox</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">iMox | MO-Floren | Moxitec | Vigamox</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Moxifloxacina rompharm | Vigamox</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Bivoxa | Floxepol | Maxiflox | Moxifloxacine Optik | Moxifur | Timilox | Vigamox</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Arox</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Vigamox</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Mo floren | Vigamox</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Vigamox</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Moxifloxacin olikla | Vigamox</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Moximac | Svoz | Vigamox</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Odycin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Bivoxa | Demoxif | Moxaflox | Moxai | Vigamox</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Vigamox</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Cytomoxan | Monafox | Moxifloxacin pharmex | Tamvelier</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Mofloren ed</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Akamoxx | Vigamox</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Floromox | Vigamox</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Flomoxad | Motarvi | Moxideka | Quimoxi</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Genfloc | Moxifloxacin ascendis</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Moxoft</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-23327981">
<a name="23327981"></a>Bratzler DW, Dellinger EP, Olsen KM, et al; American Society of Health-System Pharmacists; Infectious Disease Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Am J Health Syst Pharm</i>. 2013;70(3):195-283. doi:10.2146/ajhp120568<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-ophthalmic-pediatric-drug-information/abstract-text/23327981/pubmed" id="23327981" target="_blank">23327981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17980093">
<a name="17980093"></a>Freitas LL, Soriano E, Muccioli C, HÃ¶fling-Lima AL, Belfort R Jr. Efficacy and tolerability of a combined moxifloxacin/dexamethasone formulation for topical prophylaxis and reduction of inflammation in phacoemulsification: a comparative, double masked clinical trial. <i>Curr Med Res Opin</i>. 2007;23(12):3123-3130. doi:10.1185/030079907X242629<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-ophthalmic-pediatric-drug-information/abstract-text/17980093/pubmed" id="17980093" target="_blank">17980093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moxeza.1">
<a name="Moxeza.1"></a>Moxeza (moxifloxacin) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20598025">
<a name="20598025"></a>OzyÃ¼ncÃ¼ O, Beksac MS, Nemutlu E, Katlan D, Kir S. Maternal blood and amniotic fluid levels of moxifloxacin, levofloxacin and cefixime. <i>J Obstet Gynaecol Res</i>. 2010a;36(3):484-487.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-ophthalmic-pediatric-drug-information/abstract-text/20598025/pubmed" id="20598025" target="_blank">20598025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20418070">
<a name="20418070"></a>OzyÃ¼ncÃ¼ O, Nemutlu E, Katlan D, Kir S, Beksac MS. Maternal and fetal blood levels of moxifloxacin, levofloxacin, cefepime and cefoperazone. <i>Int J Antimicrob Agents</i>. 2010b;36(2):175-178.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-ophthalmic-pediatric-drug-information/abstract-text/20418070/pubmed" id="20418070" target="_blank">20418070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2903673">
<a name="2903673"></a>Samples JR, Meyer SM. Use of ophthalmic medications in pregnant and nursing women. <i>Am J Ophthalmol</i>. 1988;106(5):616-623.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-ophthalmic-pediatric-drug-information/abstract-text/2903673/pubmed" id="2903673" target="_blank">2903673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16257311">
<a name="16257311"></a>Silver LH, Woodside AM, Montgomery DB. Clinical Safety of Moxifloxacin Ophthalmic Solution 0.5% (VIGAMOX) in Pediatric and Nonpediatric Patients With Bacterial Conjunctivitis. <i>Surv Ophthalmol</i>. 2005;50(suppl 1):55-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-ophthalmic-pediatric-drug-information/abstract-text/16257311/pubmed" id="16257311" target="_blank">16257311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Speaker.1">
<a name="Speaker.1"></a>Speaker M, Parikh N. Prophylactic strategies for cataract surgery: a discussion of current techniques and antimicrobial agents for preventing postoperative infections. <i>J Cataract Refract Surg</i>. 2009;1-4.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8100087">
<a name="8100087"></a>Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. <i>Surv Ophthalmol</i>. 1993;37(6):435-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-ophthalmic-pediatric-drug-information/abstract-text/8100087/pubmed" id="8100087" target="_blank">8100087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vigamox.1">
<a name="Vigamox.1"></a>Vigamox (moxifloxacin) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6704011">
<a name="6704011"></a>Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. <i>Arch Ophthalmol</i>. 1984;102(4):551-553.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/moxifloxacin-ophthalmic-pediatric-drug-information/abstract-text/6704011/pubmed" id="6704011" target="_blank">6704011</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16756 Version 263.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
